Bapineuzumab 1.0 m/kg

DRUG3 trials

Sponsors

JANSSEN Alzheimer Immunotherapy Research & Development, LLC, Pfizer

Conditions

Alzheimer DiseaseAlzheimer's Disease

Phase 3

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

CompletedNCT00574132

JANSSEN Alzheimer Immunotherapy Research & Development, LLCAlzheimer's Disease

Start: 2007-12-31End: 2012-06-30Updated: 2013-11-25

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

CompletedNCT00575055

JANSSEN Alzheimer Immunotherapy Research & Development, LLCAlzheimer's Disease

Start: 2007-12-31End: 2012-04-30Updated: 2013-11-25

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

TerminatedNCT00996918

PfizerAlzheimer Disease

Start: 2009-12-31End: 2012-11-30Updated: 2014-01-01

Related Papers

Accelerating randomized clinical trials in Alzheimer’s Disease using generative machine learning model forecasts of progression

Alzheimer s & Dementia2024-12-01

Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer’s Disease

Clinical Pharmacology & Therapeutics2022-01-3114 citations

Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

Journal of Alzheimer s Disease2018-11-0632 citations

Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

Alzheimer s Research & Therapy2016-06-1638 citations

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.

2016-05-12214 citations

Alzheimer's disease assessment scale‐cognitive 11‐item progression model in mild‐to‐moderate Alzheimer's disease trials of bapineuzumab

Alzheimer s & Dementia Translational Research & Clinical Interventions2015-10-0521 citations

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials

Alzheimer s & Dementia Translational Research & Clinical Interventions2015-07-213 citations

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

New England Journal of Medicine2014-01-221940 citations